Systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis-Reference-Cited by-同舟云学术

Systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis

Published:2022-07-12 Issue:4 Volume:13 Page:234-245
ISSN:1759-1961
Container-title:Clinical and Experimental Neuroimmunology
language:en
Short-container-title:Clinical & Exp Neuroim

Author:

Drudge Christopher¹^ORCID,Zhao Melody¹^ORCID,Tanaka Satoru²^ORCID,Tanaka Nozomu²^ORCID,Otaka Hiromichi²^ORCID,Kawachi Izumi³,Häring Dieter A.⁴,Brennan Róisín⁵,Adlard Nicholas⁴^ORCID,Samjoo Imtiaz A.¹^ORCID

Affiliation:

1. EVERSANA™ Burlington Ontario Canada

2. Novartis Pharma K.K. Tokyo Japan

3. Niigata University Niigata Japan

4. Novartis Pharma AG Basel Switzerland

5. Novartis Global Services Centre Dublin Ireland

Publisher

Wiley

Subject

Neurology (clinical),Immunology and Microbiology (miscellaneous),Immunology,Neuroscience (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen3.12717

Reference43 articles.

1. Multiple sclerosis

2. Multiple Sclerosis International Federation (MSIF).Atlas of MS 3rd edition. 2020. Available from:https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms.

3. Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis

4. Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan

5. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain volume loss in relapsing multiple sclerosis: Indirect treatment comparisons of available disease-modifying therapies;2023-11-20

2. An overview of reviews with network meta-analyses comparing disease-modifying therapies for relapsing multiple sclerosis;Future Neurology;2023-09